title: Long-term (1 year) efficacy of etanercept in moderate-to-severe psoriasis. Results of a multicentric observational study in Spain.
abstract: BACKGROUND
  Information on the long-term efficacy of etanercept (ETN) treatment of moderate-to-severe psoriasis according to the Summary of Product Characteristics (SmPC) is scarce.
  
  
  OBJECTIVE
  We report the efficacy results of an observational clinical trial including 202 patients treated for 12 months with ETN according to SmPC.
  
  
  METHODS
  Concomitant topical treatment was permitted throughout the study period. Efficacy assessment was done by intention-to-treat analysis with last observation carried forward.
  
  
  RESULTS
  Mean % Body Surface Area (BSA) and Psoriasis Area and Severity Index (PASI) decreased from 39.0% and 22.2% at baseline to 7.9% and 4.4%, respectively, at 12 months. Throughout the study duration, PASI 50, PASI 75 and PASI 90 response rates ranged from 72.8% to 95.7%, 55.6% to 84.3%, and 36.1% to 62.2%, respectively. Body mass index and body weight had minor effects on treatment efficacy.
  
  
  CONCLUSIONS
  ETN treatment according to the SmPC provided sustained improvement of psoriasis throughout one year.
authors.affiliation: Dermatology Department, Hospital de la Santa Creu i Sant Pau, Sant Antoni M Claret 167, 08025 Barcelona, Catalunya, Spain.
authors.forename: Lluís
authors.initials: L
authors.lastname: Puig
authors.affiliation: Departamento de Dermatología, Hospital Virgen de la Macarena, Sevilla, Spain.
authors.forename: Francisco
authors.initials: F
authors.lastname: Camacho
authors.affiliation: Hospital Universitario Vall d'Hebron, Barcelona, Spain.
authors.forename: Vicente
authors.initials: V
authors.lastname: García-Patos
authors.affiliation: Servicio de Dermatología, Hospital Universitario Lucus Augusti, Lugo, Spain.
authors.forename: Maria Luisa
authors.initials: ML
authors.lastname: Fernández-Díaz
authors.affiliation: Servicio de Dermatología, Hospital Universitario Doctor Peset, Valencia,Spain.
authors.forename: Amparo
authors.initials: A
authors.lastname: Marquina
authors.affiliation: Departamento Médico Pfizer, Madrid, Spain.
authors.forename: Carmen
authors.initials: C
authors.lastname: García-Calvo
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D000068800:Etanercept / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000175:diagnosis* / Q000188:drug therapy*; D018570:Risk Assessment; D012720:Severity of Illness Index; D013030:Spain; D018709:Statistics, Nonparametric; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D000068800:Etanercept
keywords: efficacy; etanercept; psoriasis